Free Trial
Tyler Van Buren

Tyler Van Buren Analyst Performance

Managing Director, Senior Biotech Equity Research Analyst at TD Cowen

Tyler Van Buren is a stock analyst at TD Cowen in the medical sector, covering 23 publicly traded companies. Over the past year, Tyler Van Buren has issued 14 stock ratings, including buy and hold recommendations. While full access to Tyler Van Buren's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Tyler Van Buren's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
91 Last 9 Years
Buy Recommendations
83.33% 75 Buy Ratings
Companies Covered
23 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy83.3%75 ratings
Hold16.7%15 ratings
Sell0.0%0 ratings

Out of 90 total stock ratings issued by Tyler Van Buren at TD Cowen, the majority (83.3%) have been Buy recommendations, followed by 16.7% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
95.7% of companies on NASDAQ
22 companies
NYSE
4.3% of companies on NYSE
1 company

Tyler Van Buren, an analyst at TD Cowen, currently covers 23 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
23 companies
100.0%

Tyler Van Buren of TD Cowen specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
13 companies
56.5%
MED - DRUGS
6 companies
26.1%
MED - GENERIC DRG
1 company
4.3%
PHARMACEUTICAL PREPARATIONS
1 company
4.3%
BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC
1 company
4.3%
LARGE CAP PHARMA
1 company
4.3%

Tyler Van Buren's Ratings History at TD Cowen

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
5/5/2026Boost Price Target$43.73$60.00Buy
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4/23/2026Boost Price Target$761.04$960.00Buy
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4/7/2026Downgrade$52.23$53.00Hold
Biohaven Ltd. stock logo
BHVN
Biohaven
3/11/2026Boost Price Target$10.62$30.00Buy
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2/26/2026Boost Price Target$27.06$35.00Buy
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
2/26/2026Lower Price Target$36.82$85.00Buy
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2/13/2026Boost Price Target$48.93$45.00Hold
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2/11/2026Boost Price Target$155.80$160.00Buy
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1/29/2026Boost Price Target$139.55$145.00Buy
Biohaven Ltd. stock logo
BHVN
Biohaven
11/5/2025Lower Price Target$8.28$15.00Buy
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
10/31/2025Boost Price Target$34.29$40.00Buy
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
10/30/2025Boost Price Target$63.33$95.00Buy
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
10/23/2025Boost Price Target$121.46$125.00Buy
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
7/22/2025Initiated Coverage$21.81Buy